NCT07505303: An ongoing trial by Eccogene
This trial is ongoing. It must report results 11 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07505303 |
|---|---|
| Title | A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 23, 2026 |
| Completion date | Oct. 15, 2026 |
| Required reporting date | Oct. 15, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 29, 2026 |
| Days late | None |